$70.2 million of Net Revenue Q3 2024
+34.6% Comparable Net Revenue Growth
Both brands accelerating from Q2 2024
+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023
Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI - April 20, 2025
- Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success - April 20, 2025
- Boston Hemp Launches New Line of Premium THCa Concentrates - April 20, 2025